drugset

drugset / Trial / NCT01066546

An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease

NCT01066546 ↗

Phase 3 Terminated 5 enrolled Pfizer Medivation, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of dimebon in subjects with moderate-to-severe Alzheimer's Disease.

Timeline

Start: 2010-04
Primary completion: 2010-07
Completion: 2010-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Latrepirdine	Small molecule	20 mg	Oral

Indications